J&J Discloses New Investigations, Risperdal Agreement
Johnson & Johnson (J&J) is facing two new federal investigations into its marketing practices for a drug and a device, just as it is hammering out a settlement over off-label allegations for its antipsychotic Risperdal.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.